Analogously, Nintedanib (Cyendiv, Boehringer-Ingelheim) 2 (Chart 1), a potent triple VEGFR, PDGFR, and FGFR angiokinase inhibitor, does not elicit beneficial effects in GBM, likely due to its limited CNS penetration. Here, KDR is linked to glioblastoma.